|
業務類別
|
Biotechnology |
|
業務概覽
|
Krystal Biotech Inc is an integrated, commercial-stage biotechnology company focused on the discovery, development, manufacturing, and commercialization of genetic medicines to treat diseases with high unmet medical needs. The company usesits patented HSV-1-based gene therapy platform to create vectors that deliver therapeutic transgenes to target cells. It possesses exclusive rights to develop, manufacture, and commercialize VYJUVEK internationally. The company operates asone operating segment focused on pharmaceutical products and manufactures, markets, and sells VYJUVEK in the United States and markets and sells VYJUVEK in the European Union, and Japan. |
| 公司地址
| 2100 Wharton Street, Suite 701, Pittsburgh, PA, USA, 15203 |
| 電話號碼
| +1 412 586-5830 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.krystalbio.com |
| 員工數量
| 295 |
| Mr. Krish S. Krishnan |
Chairman of the Board, President and Chief Executive Officer |
美元 846.17K |
03/04/2026 |
| Ms. Suma M. Krishnan |
Chief Operating Officer, President, Research and Development and Director |
美元 677.50K |
03/04/2026 |
| Mr. Laurent Louis Jean Goux |
Executive Vice President and Head of International |
-- |
03/04/2026 |
| Mr. John Charles Thomas |
Executive Vice President, General Counsel, and Corporate Secretary |
-- |
03/04/2026 |
| Ms. Kathryn A. Romano |
Executive Vice President, Chief Accounting Officer and Principal Financial Officer |
美元 437.50K |
03/04/2026 |
|
|
| Mr. Daniel S. Janney |
Lead Independent Director |
03/04/2026 |
| Mr. Krish S. Krishnan |
Chairman of the Board, President and Chief Executive Officer |
03/04/2026 |
| Ms. Suma M. Krishnan |
Chief Operating Officer, President, Research and Development and Director |
03/04/2026 |
| Mr. Dino A. Rossi |
Independent Director |
03/04/2026 |
| Mr. Julian S. Gangolli |
Independent Director |
03/04/2026 |
| Dr. Christopher Mason, M.D.,PhD |
Independent Director |
03/04/2026 |
| Dr. Everett Rand Sutherland, M.D. |
Independent Director |
03/04/2026 |
| Ms. Catherine Mazzacco |
Independent Director |
03/04/2026 |
|
|
|
|
